David A. Siegel Oncorus, Inc. Transaction History

Two Sigma Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.28 - $0.45 $6,576 - $10,569	-23,488 Reduced 23.68%	75,712 $25,000
Q4 2022 Feb 14, 2023	SELL	$0.24 - $0.76 $2,136 - $6,764	-8,900 Reduced 8.23%	99,200 $24,000
Q3 2022 Nov 14, 2022	SELL	$0.85 - $1.65 $36,210 - $70,290	-42,600 Reduced 28.27%	108,100 $92,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.86 $19,240 - $34,410	-18,500 Reduced 10.93%	150,700 $190,000
Q1 2022 May 16, 2022	BUY	$1.44 - $5.62 $182,592 - $712,616	126,800 Added 299.06%	169,200 $301,000
Q4 2021 Feb 14, 2022	BUY	$5.03 - $11.63 $213,272 - $493,112	42,400 New	42,400 $223,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.